Hazardous alcohol consumption is common in HIV-infected women and is associated with significant harm. The primary objective of this application is to evaluate whether a prescription medication will reduce hazardous alcohol consumption and its consequences in HIV-infected women. The central hypothesis is that women who receive active medication (vs. placebo medication) will decrease their alcohol consumption and have improved health outcomes.
The specific aims are to determine whether a drinking-reduction medication (naltrexone or topiramate), provided to HIV-infected women with hazardous drinking (>7 drinks/wk or >4 drinks/occasion) will result in reduced alcohol consumption and improved HIV-related outcomes (antiretroviral medication adherence, reduced HIV disease progression, and reduced risky sexual behavior).This study represents the clinical trial component of our Consortiums for HIV/AIDS and Alcohol-Related Outcomes Research Trials (CHAART), a series of three inter-related projects surrounding a central Core. We propose a randomized controlled trial involving 240 HIV-infected women with hazardous drinking recruited from outpatient clinics and research settings in Chicago IL, Washington DC, Jacksonville FL, and Brooklyn NY. Women will be randomized to receive medication or placebo for 4 months;main outcomes will be assessed at 2-months, 4-months, and 7-months. Many women in the trial will also be participants in the Women's Interagency HIV Study, a large ongoing cohort of HIV-infected women. The study will build upon a currently-established pilot study in which we have established the study procedures, identified key measures, and developed the research infrastructure needed to fully implement this multi-site, randomized clinical trial. The proposed work is innovative because pharmacologic treatment for alcohol has not been evaluated in HIV-infected women outside of substance abuse treatment settings, and alcohol medication will be chosen based on an individual assessment. The expected outcome supporting the effectiveness of this treatment would transform the approach to clinical management of hazardous drinking in clinics serving HIV-infected women, and could readily be adapted to women with other chronic disease.

Public Health Relevance

This project has important public health relevance, because it addresses a common health risk factor (hazardous alcohol use) in a population at high risk for alcohol-related harm (HIV-infected women).

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AA020797-01
Application #
8211458
Study Section
Special Emphasis Panel (ZAA1-DD (04))
Program Officer
Wang, Joe
Project Start
2011-09-25
Project End
2016-08-31
Budget Start
2011-09-25
Budget End
2012-08-31
Support Year
1
Fiscal Year
2011
Total Cost
$757,068
Indirect Cost
Name
University of Florida
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Yu, Bin; Chen, Xinguang; Wang, Yan (2018) Dynamic transitions between marijuana use and cigarette smoking among US adolescents and emerging adults. Am J Drug Alcohol Abuse 44:452-462
Cohen, Ronald A; Siegel, S; Gullett, J M et al. (2018) Neural response to working memory demand predicts neurocognitive deficits in HIV. J Neurovirol 24:291-304
Wang, Yan; Chen, Xinguang; Hahn, Judith A et al. (2018) Phosphatidylethanol in Comparison to Self-Reported Alcohol Consumption Among HIV-Infected Women in a Randomized Controlled Trial of Naltrexone for Reducing Hazardous Drinking. Alcohol Clin Exp Res 42:128-134
Gullett, Joseph M; Lamb, Damon G; Porges, Eric et al. (2018) The Impact of Alcohol Use on Frontal White Matter in HIV. Alcohol Clin Exp Res 42:1640-1649
Szymkowicz, Sarah M; Woods, Adam J; Dotson, Vonetta M et al. (2018) Associations between subclinical depressive symptoms and reduced brain volume in middle-aged to older adults. Aging Ment Health :1-12
Szymkowicz, Sarah M; Dotson, Vonetta M; McLaren, Molly E et al. (2017) Precuneus abnormalities in middle-aged to older adults with depressive symptoms: An analysis of BDI-II symptom dimensions. Psychiatry Res Neuroimaging 268:9-14
Canidate, Shantrel S; Carnaby, Giselle D; Cook, Christa L et al. (2017) A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders. Alcohol Clin Exp Res 41:466-472
Helian, Shanjun; Brumback, Babette A; Cook, Robert L (2017) Sparse canonical correlation analysis between an alcohol biomarker and self-reported alcohol consumption. Commun Stat Simul Comput 46:7924-7941
Cook, Robert L; Weber, Kathleen M; Mai, Dao et al. (2017) Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results. Contemp Clin Trials 60:72-77
Hu, Xingdi; Chen, Xinguang; Cook, Robert L et al. (2016) Modeling Drinking Behavior Progression in Youth with Cross-sectional Data: Solving an Under-identified Probabilistic Discrete Event System. Curr HIV Res 14:93-100

Showing the most recent 10 out of 14 publications